Gene Therapy: Taking it to the Lesion

A biochemist's unintended wander into gene therapy may have achieved one of gene therapy's long-sought goals: a way to deliver cytocidal genes to metastatic cancer cells dispersed throughout the body while leaving normal cells unharmed. Fred Hall of the department of surgery at the University of Southern California in Los Angeles, has developed an ingenious seek-and-destroy cancer vector. What makes Hall's attempt at tumor-targeted gene delivery out of the ordinary is that his vector doesn't hom

Written byTom Hollon
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The idea for his vector came during a conversation with Gordon about the need for a gene therapy vector that would accumulate in tumors after being injected intravenously. Anderson had been calling for such a vector for years. Recalling work he'd done on von Willebrand's factor, Hall tossed out a top-of-the-head remark intended as a joke. "I could design a vector so it would stick to collagen," he remembers laughingly saying, "but who wants to transduce straw?" His jest unexpectedly earned not laughter but silence. In a pause of reflection, it dawned on both of them that targeting collagen might be uncommonly useful.

In healthy tissue collagen is buried under cells, proteins and layers and is exposed only in instances of tissue disruption. "Every lesion of every major disease has disruption of collagen," Hall notes, adding that for cancer the connection to collagen is threefold. Cancer brings about new blood ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies